Literature DB >> 8077322

Pit-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas.

K E Friend1, Y K Chiou, E R Laws, M B Lopes, M A Shupnik.   

Abstract

Thirty-four human pituitary adenomas were examined for the presence of Pit-1 mRNA via Northern analysis. All tumors that were immunoreactive with either human (h) PRL or hGH antiserum contained Pit-1 mRNA (8 of 8) as did a small percentage of alpha-subunit only (1 of 3) and null tumors (1 of 9). Two tumors that contained TSH beta mRNA by RNAse protection assay also contained Pit-1 mRNA. Tumors that were immunoreactive with antiserum for hACTH, hFSH beta, or hLH beta without containing PRL, GH, or TSH beta were uniformly Pit-1 negative (0 of 14). Although RNA from the majority of Pit-1-positive tumors (10 of 11) contained primarily a 2.4-kilobase (kb) Pit-1 mRNA transcript, 1 tumor appeared to contain a 1.6-kb mRNA. Analysis of human pituitary autopsy specimens revealed no 1.6-kb Pit-1 mRNA, indicating that this variant may be tumor specific. The wide variety of serum PRL, GH, and insulin-like growth factor-I levels in patients with Pit-1-positive tumors suggests that although Pit-1 is necessary for PRL and GH production, it is not uniformly associated with hormone production, as determined by either immunohistochemistry or elevated serum levels. The expression of Pit-1 mRNA in a small fraction of null and alpha-subunit only tumors indicates that there may be a previously unsuspected diversity of origin within these particular subsets of adenomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8077322     DOI: 10.1210/jcem.77.5.8077322

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Pit-1 positive alpha-subunit positive nonfunctioning human pituitary adenomas: a dedifferentiated GH cell lineage?

Authors:  R Y Osamura; S Tahara; K Komatsubara; Y Itoh; H Kajiwara; R Kurotani; N Sanno; A Teramoto
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

2.  Double adenomas of the pituitary: transcription factors Pit-1, T-pit, and SF-1 identify cytogenesis and differentiation.

Authors:  R A Jastania; K O Alsaad; M Al-Shraim; K Kovacs; S L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Advances and controversies in the classification and grading of pituitary tumors.

Authors:  E R Laws; D L Penn; C S Repetti
Journal:  J Endocrinol Invest       Date:  2018-06-01       Impact factor: 4.256

Review 4.  My approach to pathology of the pituitary gland.

Authors:  N Y Y Al-Brahim; S L Asa
Journal:  J Clin Pathol       Date:  2006-12       Impact factor: 3.411

Review 5.  Role of transcription factors in the pathogenesis of pituitary adenomas: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

6.  Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors.

Authors:  M T McDermott; B R Haugen; D F Gordon; W M Wood; N S Brown; C A Bauer; M J Garrity; B K Kleinschmidt-DeMasters; K O Lillehei; M H Samuels; T M Bright; E C Ridgway
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

Review 7.  Molecular determinants of pituitary cytodifferentiation.

Authors:  S L Asa; S Ezzat
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

8.  Estrogen regulates the expression of several different estrogen receptor mRNA isoforms in rat pituitary.

Authors:  K E Friend; L W Ang; M A Shupnik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 9.  Gene expression in prolactinomas: a systematic review.

Authors:  Justin Seltzer; Thomas C Scotton; Keiko Kang; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

Review 10.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.